Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
CLEOCIN HYDROCHLORIDE vs CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, a lincosamide antibiotic. It reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
1200-2700 mg/day IV divided every 6-12 hours; typical adult dose: 600-900 mg IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
Terminal elimination half-life is 2-4 hours in adults with normal hepatic and renal function. In patients with severe hepatic impairment, half-life may increase to 8-12 hours. Renal impairment generally does not significantly alter half-life. In neonates, half-life ranges from 8-20 hours depending on gestational age.
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Approximately 10% of the administered dose is excreted unchanged in urine via glomerular filtration; about 90% is metabolized hepatically to inactive metabolites, which are excreted in bile and feces. Biliary excretion accounts for approximately 80% of total elimination, with enterohepatic recirculation.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic